PRAX
Praxis Precision Medicines Inc (PRAX)
Healthcare • NASDAQ • $330.02-0.98%
- Symbol
- PRAX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $330.02
- Daily Change
- -0.98%
- Market Cap
- $9.20B
- Trailing P/E
- N/A
- Forward P/E
- -37.54
- 52W High
- $356.00
- 52W Low
- $35.21
- Analyst Target
- $636.82
- Dividend Yield
- N/A
- Beta
- N/A
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molec…
Company websiteResearch PRAX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.